Saturday 17 October 2026 Export KURA’s income statement to Excel — free account

Kura Oncology, Inc.

Kura Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.5 million, up 25.2% from fiscal 2024. In the quarter to June 2026, revenue grew 36.5%, EPS fell 2.67%, free cash flow fell 109.1% and total debt rose 1.76%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

9.08 0.62 −6.39%

Follow KURA

Alert me

Market cap: $862.9M
P/E: 0.0×
Fwd P/E: −2.5×
Dividend yield: —
F-score: n/a
Altman Z: −1.56
Beneish M: −1.35
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 2.35

Total sells 3.84

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	2	—	—
Sell	5	2	6	—	—	—	4	1	—	2	6	—

Insider Ownership 2.66%

Capital & Financial Ratios $m

Market Cap 862.92

Revenue 77.23

Net Income (296.77)

Free Cash Flow (117.43)

Net Debt (509.23)

Current Ratio 4.73

Debt/Equity 0.20

P/E ratio 0.00

Fwd P/E (2.48)

P/S ratio 10.45

P/B ratio 16.66

Past 5Y EPS Growth —

This Y EPS Growth (2.12%)

Next Y EPS Growth 25.35%

Next Y revenue growth 42.45%

Next 5Y EPS Growth 15.46%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 97.27%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	424	727	667	519
Receivables	—	2	9	9
Inventory	—	—	0	2
Other	—	—	—	—
	432	745	709	559

	2023	2024	2025	Q'26
Payables	34	1	5	2
ST’ Debt	—	3	—	4
Other	—	24	49	55
	35	79	117	118

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	7.81%	(22.20%)	(25.45%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	18	21	—	—	—
’25	14	15	21	17	67

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(86)	(63)	—	—	—
’25	(72)	(29)	(81)	117	(64)
’24	(49)	(43)	(43)	269	134
’23	(36)	(26)	(29)	(34)	(125)
’22	(32)	(30)	(21)	(27)	(110)
’21	(29)	(28)	(25)	(23)	(105)
’20	(20)	(15)	(17)	(18)	(70)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(86)	(63)	—	—	—
’25	(72)	(30)	(83)	115	(71)
’24	(49)	(43)	(43)	269	134
’23	(36)	(26)	(29)	(34)	(125)
’22	(32)	(31)	(21)	(27)	(111)
’21	(29)	(28)	(25)	(23)	(106)
’20	(20)	(15)	(18)	(19)	(72)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.83)	(0.77)	—	—	—
’25	(0.66)	(0.75)	(0.85)	(0.92)	(3.18)
’24	(0.59)	(0.59)	(0.63)	(0.22)	(2.02)
’23	(0.50)	(0.53)	(0.50)	(0.55)	(2.08)
’22	(0.49)	(0.52)	(0.53)	(0.49)	(2.03)
’21	(0.46)	(0.51)	(0.50)	(0.49)	(1.97)
’20	(0.42)	(0.40)	(0.42)	(0.45)	(1.69)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2.50	5.60	10.20	12.65	6.35	12.02	10.41	7.41	8.42	5.41	Analyst estimates 2026–2028 Powerpack
	High	8.90	17.50	24.03	21.42	43.00	40.01	19.93	15.06	24.17	12.49
People
People	Employees	25	32	46	60	89	121	133	142	192	260
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.28	0.26
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	54	67
	Gross margin, %	0.00	0.00	0.00	—	0.00	0.00	0.00	—	100.00	99.92
	EBT	(28)	(35)	(60)	(63)	(90)	(130)	(136)	(153)	(172)	(278)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(319.15)	(412.51)
	Net income	(28)	(35)	(60)	(63)	(90)	(130)	(136)	(153)	(174)	(279)
	Depreciation	0	0	(2)	(1)	1	5	2	(9)	(12)	(7)
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.63	0.77
	Earnings	(1.47)	(1.52)	(1.72)	(1.51)	(1.69)	(1.97)	(2.03)	(2.08)	(2.02)	(3.18)
	Cash flow	(1.36)	(1.22)	(1.38)	(1.31)	(1.32)	(1.58)	(1.64)	(1.70)	1.56	(0.73)
	Capex	0.00	0.00	0.00	0.00	(0.04)	(0.02)	(0.01)	0.00	(0.01)	(0.08)
	Free cash flow	(1.36)	(1.22)	(1.38)	(1.31)	(1.36)	(1.59)	(1.65)	(1.71)	1.55	(0.81)
	Book value	3.04	3.44	4.57	5.22	11.51	7.64	6.27	5.43	4.80	1.99
	Shares, m	19	23	35	42	53	66	67	73	86	88
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	0.00	0.00
	P/S	—	—	—	—	—	—	—	—	0.00	13.50
	P/B	—	—	—	—	—	—	—	—	1.81	5.23
	EV/Sales	—	—	—	—	—	—	—	—	0.00	3.82
	EV/FCF	—	—	—	—	—	—	—	—	0.24	(3.65)
Cash, $m
Cash, $m	Operating cash flow	(25)	(28)	(49)	(55)	(70)	(105)	(110)	(125)	134	(64)
	Capex	—	—	—	—	(2)	(1)	(1)	0	0	(7)
	Free cash flow	(25)	(28)	(49)	(55)	(72)	(106)	(111)	(125)	134	(71)
Balance, $m
Balance, $m	Working capital	63	85	168	224	611	500	422	397	666	592
	Total debt	7	7	8	8	7	7	11	9	10	10
	Net debt	(60)	(86)	(171)	(229)	(626)	(511)	(427)	(415)	(718)	(658)
	Shareholders’ equity	57	80	161	219	611	507	420	397	414	174
Returns, %
Returns, %	ROA	(35.09)	(42.78)	(43.45)	(29.76)	(20.16)	(22.09)	(27.43)	(33.72)	(28.78)	(37.19)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(39.66)	(51.83)	(50.19)	(33.25)	(21.60)	(23.35)	(29.31)	(37.34)	(42.91)	(94.82)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AKTS Aktis Oncology, Inc.	$890.5M	— (loss-making)	— (loss-making)	—	n/m	−12.77% (below 0%: shrinking)	100.00%	(853.99%)	Compare
ANRO Alto Neuroscience, Inc.	$887.7M	— (loss-making)	—	—	n/m	−43.41% (below 0%: shrinking)	—	0.00%	Compare
RIGL Rigel Pharmaceuticals, Inc.	$882.6M	2.6×	7.9×	−22.60% (below 0%: shrinking)	−72.07% (below 0%: shrinking)	−229.99% (below 0%: shrinking)	89.17%	29.95%	Compare
JBIO Jade Biosciences, Inc.	$875.1M	— (loss-making)	—	—	n/m	−115.11% (below 0%: shrinking)	0.00%	0.00%	Compare
MLTX MoonLake Immunotherapeutics	$873.2M	— (loss-making)	—	—	n/m	−1.89% (below 0%: shrinking)	0.00%	0.00%	Compare
GLUE Monte Rosa Therapeutics, Inc.	$863.4M	— (loss-making)	— (loss-making)	−61.33% (below 0%: shrinking)	n/m	−34.11% (below 0%: shrinking)	100.00%	(547.84%)	Compare
KURA Kura Oncology, Inc.	$862.9M	— (loss-making)	— (loss-making)	+36.54% (above 0%: growing)	n/m	−109.05% (below 0%: shrinking)	98.84%	(349.77%)
ALMS Alumis Inc.	$842.4M	— (loss-making)	— (loss-making)	−37.66% (below 0%: shrinking)	n/m	+23.59% (above 0%: growing)	100.00%	(8,956.38%)	Compare
VSTM Verastem, Inc.	$835.9M	— (loss-making)	— (loss-making)	+1,775.43% (above 0%: growing)	n/m	−34.43% (below 0%: shrinking)	89.92%	(81.62%)	Compare
Median of peers	$874.1M	—	—	−30.13%	—	−34.27%	89.92%	(40.81%)

All 614 Biotechnology stocks →

Kura Oncology, Inc. (KURA) key facts

Concern: Kura Oncology, Inc. reported a net loss of $278.7 million, or a loss of $3.18 per share, for fiscal 2025.
Strength: Kura Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.5 million, up 25.2% from fiscal 2024.
Kura Oncology, Inc. (KURA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, KURA traded at $9.08, a market capitalization of $862.9 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 10.4× sales.
Return on equity was −94.8% and debt-to-equity 0.20.
Its Altman Z-score is −1.56 (distress zone) for fiscal 2025.